| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $2.6M | +49.7% | +163.1% |
| SG&A Expense | $1.5M | -0.1% | +154.5% |
| Operating Income | -$4.1M | -26.6% | -159.9% |
| Net Income | -$3.4M | -40.1% | -163.6% |
| EPS (Basic) | -$0.48 | -37.1% | -29.7% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $127.7M | +223.2% | +2020.9% |
| Current Assets | $144.1M | +168.1% | +2274.0% |
| Total Assets | $144.2M | +167.7% | +2275.7% |
| Current Liabilities | $2.6M | +62.2% | — |
| Total Liabilities | $2.6M | +58.6% | +135.1% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$8.8M | — | — |
| Investing Cash Flow | -$1.3M | — | — |
| Financing Cash Flow | $92.0M | — | — |
| $141.6M |
| +171.2% |
| +2761.6% |